“It is not at all clear that Merck is doing anything other than extending its monopoly power over the drug,” Warren wrote to Kathi Vidal, director of the United States Patent and Trademark Office (PTO) in the letter sent on Wednesday

Dealing with the seismic effects of the COVID-19 pandemic, the biopharma industry continues to break new ground during a transformative era of product innovation.

The drug was being tested in combination with androgen deprivation therapy and Xtandi, made by Pfizer Inc and Astellas Pharma Inc., in patients with hormone-sensitive prostate cancer that has spread to other parts of the body.

Gilead receives the rights to exclusively license EVOQ’s NanoDisc Technology to develop and commercialize immunotherapy products for rheumatoid arthritis and lupus.

A combination of Moderna’s melanoma vaccine and Merck’s immunotherapy Keytruda cut the risk of skin cancer’s recurrence or death by 44% compared with Keytruda alone in a mid-stage trial.

“We believe that subcutaneous formulation has the potential to be novel, non-obvious and useful, which means we would get a new patent for it,” according to Merck CFO Caroline Litchfield.

The companies hope pairing the capabilities of the two platforms will allow for the development of conditionally-activated investigational bispecific cancer therapies.

Elevation Oncology, Janssen, Merck and Teclison discuss the latest innovations in immuno-oncology.

Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial, the company said.

Thursday morning, Takeda reported its quarterly sales ending June 30, 2022. The company reported a 2.4% increase in revenue for the quarter from the same period in 2021, as well as changes to its pipeline, including a decision to drop a cancer therapeutic developed with Turnstone Biologics.